Drug Trial Radar · NCT07612891
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
Last checked: Nov 20, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
201
Planned (sponsor's estimate)
Start
Jul 4, 2025
Primary completion
Feb 4, 2028
Study completion Feb 4, 2028
Sponsor
- Lead sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-6452 in adult patients with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) advanced/metastatic breast cancer or locally advanced/metastatic solid tumor.
Conditions
- Breast Cancer (Locally Advanced or Metastatic)
- Advanced Solid Cancers
- Metastatic (Stage IV) Breast Cancer
- Ovarian Cancer
- Endometrial Cancer
Interventions
INV-6452Drug
once daily orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Maximum tolerated dose (MTD)Time frame: Within first 28 days of treatment
- Phase 1: Recommended dose range (RDR)Time frame: 12 months
- Phase 2: Evaluate overall response rate (ORR)Time frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.